Live
FierceBiotechAscendis axes IL-2 program in retreat from oncology expansionPharmaVoiceNovo hikes guidance on Wegovy pill’s fast sales startEndpoints NewsAmgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in GermanyFierceBiotechEntrada's stock craters as DMD data underperform expectations, handing advantage to NovartisFierceBiotechRoche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnosticsPromega BlogWhat Counts as EvidenceFierceBiotechFrom drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’Lonza NewsBMS Licenses SYNtecan Linker-Payload Platform from Lonza - Contract PharmaIlluminaAi In Genomics Market Is Going to Boom | Illumina, IBM, Google - openPR.comEndpoints NewsAtara, Pierre Fabre's cell therapy to get another shot at FDA approvalFierceBiotechInsulet boosts guidance in Q1 update as it grapples with recall sagaPharmaVoiceLilly, Gilead lead pharma’s M&A boom
Thermo Fisher Mar 22, 2026

Is Thermo Fisher Scientific (TMO) Pricing Look Attractive After Recent Share Price Weakness - Yahoo Finance

Is Thermo Fisher Scientific (TMO) Pricing Look Attractive After Recent Share Price Weakness - Yahoo Finance

Body unavailable. Use the original source.